Pencil Beam Scanning in Patients With Renal Tumors

Overview

This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.

Full Title of Study: “Pilot Study of Pencil Beam Scanning Proton Beam Radiation Therapy in Patients With Renal Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2022

Detailed Description

Patients with renal tumors including Wilms and clear cell sarcoma of the kidney (CCSK) are treated with multimodality therapy which may include surgery, chemotherapy, and radiation. While long-term disease control is excellent, these patients remain at risk for early and late toxicities partially from radiation. There have been no significant changes to traditional photon radiation fields, which encompass the post-operative bed, anterior abdomen, and vertebral body. Proton beam radiation using pencil beam scanning, which is characterized by Bragg peak dose deposition and high conformality of dose to target regions, is ideally suited to treat the retroperitoneum. This pilot study evaluates pencil beam scanning proton therapy (PBS-PT) to:

- result in low acute gastrointestinal toxicity in patients receiving radiation therapy for renal tumors as measured by laboratory evaluations, clinician-assessed, and patient reported health related quality of life outcomes

- decrease the duration of radiation therapy

- compare doses to organs at risk (OARs) using PBS-PT as compared to traditional photon fields

Interventions

  • Other: Proton beam radiation using pencil beam scanning
    • Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions

Arms, Groups and Cohorts

  • Other: Renal tumors
    • Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.

Clinical Trial Outcome Measures

Primary Measures

  • Occurrence of any non-hematologic toxicity that occurs within 90 days following the start of proton therapy assessed with with NCI Common toxicity criteria (CTC Version 4.0) grades].
    • Time Frame: 90 days
    • Acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors. Acute toxicity is defined as any non-hematologic toxicity that occurs within 90 days following the start of proton therapy. NCI Common toxicity criteria (CTC Version 4.0) grades will be employed. Individual category content listings are available to investigators at http://ctep.cancer.gov, with attention to the following System Organ Classes and CTCAE Adverse Events: General Disorders and Administration Site Conditions, Hepatobiliary Disorders, Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Renal and Urinary Disorders, Injury, poisoning, or procedural complications, Metabolism and nutrition disorders, and Benign, Malignant, and Unspecified Neoplasms.

Participating in This Clinical Trial

Inclusion Criteria

  • Less than 30 years of age
  • Diagnosis

a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including

1. Any patient with favorable histology (FH), stage III disease

2. Any patient with focal or diffuse anaplasia

3. Any patient with CCSK

  • The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

Exclusion Criteria

  • Prior radiotherapy to the region of the study cancer
  • Chemotherapy administered for diagnosis of Wilms tumor or CCSK
  • Pregnant or breastfeeding

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Hospital of Philadelphia
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Christine Hill-Kayser, MD, Principal Investigator, Children’s Hospital of Philadelphia
  • Overall Contact(s)
    • Christine Hill-Kayser, MD, 215-590-2810, hill@uphs.upenn.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.